Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Saroglitazar Magnesium in Moderate Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
NCT06825559Phase 1Recruiting
- Sponsor
- Zydus Therapeutics
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of saroglitazar in cholestatic liver disease (CLD), sponsored by Zydus Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration at Day 29, Time to Maximum Plasma Concentration at Day 29 and 7 more. Started Aug 2025; status: recruiting.
02
Drugs
saroglitazar
03
Conditions
cholestatic liver disease (CLD)
Beyond the preview
Go deeper on NCT06825559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825559.